<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03482232</url>
  </required_header>
  <id_info>
    <org_study_id>PI16/00816</org_study_id>
    <nct_id>NCT03482232</nct_id>
  </id_info>
  <brief_title>Consequences of Doing What Should Not be Done in Primary Care</brief_title>
  <acronym>SOBRINA</acronym>
  <official_title>Consequences of Doing What Should Not be Done in Primary Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Miguel Hernandez de Elche</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Osasunbidea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Servicio Madrileño de Salud, Madrid, Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondo de Investigacion Sanitaria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AQuAS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Agencia de Calidad Sanitaria de Andalucía</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministerio de Sanidad, Servicios Sociales e Igualdad</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Servicio Aragonés de Salud</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Consellería Sanitat, Generalitat Valenciana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MurciaSalud</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Osakidetza</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Castilla-La Mancha Health Service</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad Miguel Hernandez de Elche</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective observational study in a random selection of 5% of digital records active
      between 2014 and 2017 to quantify the frequency of Do not do primary care recommendations,
      calculating the over-cost related to them and study reviewing a random selection of cases
      previously identified to determine whether patient suffered adverse events and their
      over-cost.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Basement: Overuse subjected patients to unnecessary risk without promoting a sufficient
      clinical benefit and over-cost. The Less is More Medicine movement has led to the
      identification of Do not do in different specialties, also in primary care.

      Objective: To analyze the impact of errors (overuse rates based in Do not do recommendations)
      in clinical practice.

      Method: Retrospective observational study in a random selection of 5% of digital records
      active between 2014 and 2017 to quantify the frequency of Do not do primary care
      recommendations, calculating the over-cost related to them. Retrospective study reviewing a
      random selection of cases previously identified to determine whether patient suffered adverse
      events and their over-cost.

      Setting. Primary care in Andalucía, Aragón, Castilla La Mancha, Comunidad Valenciana, Madrid,
      Murcia, Navarra y País Vasco, eight autonomous communities in Spain.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Medical overuse</measure>
    <time_frame>Three years</time_frame>
    <description>Inadequate prescriptions of antimicrobials, mucolytics, lipid-lowering-drugs, ibuprofen or paracetamol in some specific cases defined as overuse</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Medical overuse</measure>
    <time_frame>Three years</time_frame>
    <description>Inadequate test for lumbalgia or prostate cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events as consequence of inadequate clinical decision [Safety]</measure>
    <time_frame>Three years</time_frame>
    <description>Patients suffering hurt due to inadequate prescription or inadequate test. Inadequate prescriptions or tests as defined by Do-not-Do recommendations. These were defined by Spanish Primary Care Scientific Societies</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">750000</enrollment>
  <condition>Overdose</condition>
  <condition>Adverse Event</condition>
  <arm_group>
    <arm_group_label>Patients visiting GP</arm_group_label>
    <description>All patients visiting GP. The frequency of some drugs and diagnosis tests include in the Do-Not-Do recommendations will be analyzed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient visiting pediatricians</arm_group_label>
    <description>All patients visiting pediatricians (0 to 14 years old). The frequency of some drugs and diagnosis tests include in the Do-Not-Do recommendations will be analyzed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benzodiazepines</intervention_name>
    <description>Benzodiazepines for insomnia, agitation or delirium in people older than 65</description>
    <arm_group_label>Patients visiting GP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Non-steroidal anti-inflammatory drugs</intervention_name>
    <description>Non-steroidal anti-inflammatory drugs in patients with cardiovascular disease, chronic kidney disease, hypertension, heart failure or liver cirrhosis</description>
    <arm_group_label>Patients visiting GP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paracetamol</intervention_name>
    <description>paracetamol 1g for more than 3 days</description>
    <arm_group_label>Patients visiting GP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antimicrobial agent</intervention_name>
    <description>antibiotic in acute bronchitis when the patient does not suffer from COPD, heart failure, diabetes or kidney disease or is undergoing active chemotherapy</description>
    <arm_group_label>Patients visiting GP</arm_group_label>
    <other_name>Antibiotics</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lipid-lowering drug</intervention_name>
    <description>Lipid-lowering drugs in patients older than 75 years without previous cardiovascular events</description>
    <arm_group_label>Patients visiting GP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Prostate cancer</intervention_name>
    <description>Screening for prostate cancer in asymptomatic patients</description>
    <arm_group_label>Patients visiting GP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Lumbago</intervention_name>
    <description>image tests in non-specific lumbago</description>
    <arm_group_label>Patients visiting GP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antimicrobial agent</intervention_name>
    <description>antibiotics for pharyngitis (infants)</description>
    <arm_group_label>Patient visiting pediatricians</arm_group_label>
    <other_name>Antibiotics</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mucolytic</intervention_name>
    <description>mucolytics, antitussives or antibiotics for upper respiratory infections (infants)</description>
    <arm_group_label>Patient visiting pediatricians</arm_group_label>
    <other_name>Mucolytics</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen and paracetamol</intervention_name>
    <description>treatment with ibuprofen and paracetamol (infants)</description>
    <arm_group_label>Patient visiting pediatricians</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients data codified in the primary care databases (BDCAP and BIFAP)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients visiting GPs

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JOSE J MIRA, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNIVERSIDAD MIGUEL HERNANDEZ</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>JOSE J MIRA, PhD</last_name>
    <phone>+34966658984</phone>
    <email>jose.mira@umh.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>IRENE CARRILLO, Psych</last_name>
    <phone>+34966658984</phone>
    <email>icarrillo@umh.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>FISABIO</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03202</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidad Miguel Hernández</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03202</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Gibson R. The human cost of overuse. BMJ. 2014 May 6;348:g2975. doi: 10.1136/bmj.g2975.</citation>
    <PMID>24803401</PMID>
  </reference>
  <reference>
    <citation>Brownlee S, Chalkidou K, Doust J, Elshaug AG, Glasziou P, Heath I, Nagpal S, Saini V, Srivastava D, Chalmers K, Korenstein D. Evidence for overuse of medical services around the world. Lancet. 2017 Jul 8;390(10090):156-168. doi: 10.1016/S0140-6736(16)32585-5. Epub 2017 Jan 9. Review.</citation>
    <PMID>28077234</PMID>
  </reference>
  <reference>
    <citation>Segal JB, Bridges JF, Chang HY, Chang E, Nassery N, Weiner J, Chan KS. Identifying possible indicators of systematic overuse of health care procedures with claims data. Med Care. 2014 Feb;52(2):157-63. doi: 10.1097/MLR.0000000000000052.</citation>
    <PMID>24374418</PMID>
  </reference>
  <reference>
    <citation>Rosenberg A, Agiro A, Gottlieb M, Barron J, Brady P, Liu Y, Li C, DeVries A. Early Trends Among Seven Recommendations From the Choosing Wisely Campaign. JAMA Intern Med. 2015 Dec;175(12):1913-20. doi: 10.1001/jamainternmed.2015.5441. Erratum in: JAMA Intern Med. 2015 Dec;175(12):2003.</citation>
    <PMID>26457643</PMID>
  </reference>
  <reference>
    <citation>Grady D, Redberg RF. Less is more: how less health care can result in better health. Arch Intern Med. 2010 May 10;170(9):749-50. doi: 10.1001/archinternmed.2010.90.</citation>
    <PMID>20458080</PMID>
  </reference>
  <reference>
    <citation>Aranaz-Andrés JM, Aibar C, Limón R, Mira JJ, Vitaller J, Agra Y, Terol E. A study of the prevalence of adverse events in primary healthcare in Spain. Eur J Public Health. 2012 Dec;22(6):921-5. doi: 10.1093/eurpub/ckr168. Epub 2011 Nov 29.</citation>
    <PMID>23180803</PMID>
  </reference>
  <reference>
    <citation>Newton EH, Zazzera EA, Van Moorsel G, Sirovich BE. Undermeasuring Overuse--An Examination of National Clinical Performance Measures. JAMA Intern Med. 2015 Oct;175(10):1709-11. doi: 10.1001/jamainternmed.2015.4025.</citation>
    <PMID>26258406</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2018</study_first_submitted>
  <study_first_submitted_qc>March 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Miguel Hernandez de Elche</investigator_affiliation>
    <investigator_full_name>José Joaquín Mira</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>patient safety</keyword>
  <keyword>quality assurance</keyword>
  <keyword>overuse</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Anti-Infective Agents</mesh_term>
    <mesh_term>Hypolipidemic Agents</mesh_term>
    <mesh_term>Expectorants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Public and safety patient researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

